“Anastomosis Devices Market Report is set to have rapid growth due the rising surgical procedures along with growing incidence of cardiovascular and gastrointestinal diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Anastomosis Devices Market Report : Forecast By Product (Disposable, Reusable), By Application (Cardiovascular Surgery, Gastrointestinal Surgery), By Region, Competitive Landscape, and Segment Forecasts.

The global Anastomosis Devices market is poised for rapid growth between 2019 and 2029. The increase in the number of cardiovascular surgical procedures performed and an increase in the prevalence of chronic diseases, such as gastrointestinal and cardiac disorders, are the main factors driving the global market for anastomotic devices worldwide.

According to the European Commission, about 181,000 bypass anastomoses for heart revascularization procedures were performed in the 25 EU Member States in 2016. Among them, Germany conducted about 51,000 cardiac bypass operations in 2016. This will probably fuel the demand of anastomotic devices in the near future.

Furthermore, rapid technological progress is expected to be a favorable reimbursement scenario for cardiac procedures, including coronary artery bypass grafting (CABG), open heart valve replacement and angioplasty, in regions developed for encourage the adoption of anastomotic devices during the forecast period. However, the complications associated with anastomosis, such as anastomotic leaks, are expected to hamper the global market for anastomotic devices.

Leading companies featured in the report include Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; and Ethicon US, LLC.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever